GlassScriptPhysician profile
Sima Jivan Patel
NPI 1912263450
$21,113.29
in general payments reported to CMS, 2019-2025
36 companies · $5,817 in 2025
The $5,817 reported for 2025 was more than what 87% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $776 · 2021: $1,989 · 2022: $3,284 · 2023: $4,072 · 2024: $4,425 · 2025: $5,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,210.43 |
| Education | $103.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,253.53 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $3,727.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $3,460.71 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Kaleo, INC. | $1,051.16 | 2019-2024 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $1,013.67 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $868.06 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $746.49 | 2021-2025 | Takhzyro, Cuvitru |
| Pfizer INC. | $589.13 | 2019-2023 | |
| Amgen INC. | $477.48 | 2022-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $468.10 | 2020-2022 | |
| Csl Behring | $430.22 | 2023-2025 | Haegarda, Andembry, Kcentra |
| Blueprint Medicines Corporation | $399.14 | 2024-2025 | Ayvakit |
| Genentech USA, INC. | $388.45 | 2019-2025 | Xolair |
| Leo Pharma INC. | $359.95 | 2024-2025 | Adbry, Anzupgo |
| Ars Pharmaceuticals Operations, INC. | $256.82 | 2025 | Neffy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $236.46 | 2020-2025 | |
| Biocryst US Sales Co., LLC | $207.62 | 2022-2025 | Orladeyo |
| Galderma Laboratories, L.P. | $166.07 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $148.30 | 2021-2025 | Ruconest |
| Stryker Corporation | $132.13 | 2019 | |
| Lilly USA, LLC | $116.87 | 2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $114.23 | 2023-2024 | Ryaltris |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Alk-Abello, INC | $91.33 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $58.50 | 2020-2021 | |
| Abbvie INC. | $50.80 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.28 | 2020 | |
| Cycle Pharmaceuticals INC | $27.52 | 2024 | Sajazir |
| Grifols USA, LLC | $25.16 | 2025 | Xembify |
| Insulet Corporation | $23.85 | 2023 | Omnipod |
| Incyte Corporation | $21.18 | 2021 | |
| Covis Pharma Gmbh | $21.12 | 2021 | |
| Horizon Therapeutics Plc | $20.88 | 2021 | |
| Phadia US INC. | $17.32 | 2024 | Immunocap |
| Merck Sharp & Dohme LLC | $12.86 | 2019 | |
| Organon LLC | $4.59 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sima Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.